{"id":44278,"date":"2024-10-15T12:06:00","date_gmt":"2024-10-15T10:06:00","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=44278"},"modified":"2024-10-24T12:06:36","modified_gmt":"2024-10-24T10:06:36","slug":"zealand-pharma-with-major-updates-and-saniona-received-milestone-payment","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/","title":{"rendered":"Zealand Pharma with major updates and Saniona received milestone payment"},"content":{"rendered":"\n

NORDIC | BIOTECH & HEALTHCARE<\/strong> Your insights into listed Danish & Nordic biotech & healthcare stocks.<\/em><\/p>\n\n\n\n

In the past week, the Nordic biotech and healthcare stocks declined 1.1%. Most notably, Zealand Pharma initiated two new phase 3 studies in MASH with Survodutide, while FDA approval for Dasiglucagon was delayed. Further, Acarix got a new order, Genmab new price targets, Saniona received a milestone payment, and Biosergen completed enrollment of a trial with BSG005.<\/strong><\/p>\n\n\n\n

Only 4 of the 22 Danish biotech companies had a positive share price development the past week and 10 companies have had a positive share price performance year-to-date.<\/strong> Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance.<\/strong> Five <\/strong><\/span>Danish healthcare stocks with +100% YTD return.<\/strong><\/p>\n\n\n\n

\n
Register for the Nordic I Impact newsletter here.<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Danish company news<\/strong><\/p>\n\n\n\n

Acarix AB<\/a><\/strong><\/p>\n\n\n\n

Multi-Location Customer Places Order of the Acarix CADScor System with Goal to Scale Usage (Link<\/a>)<\/p>\n\n\n\n

Ascendis Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/p>\n\n\n\n

Biosergen<\/a><\/strong><\/p>\n\n\n\n

Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial<\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Cessatech<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/p>\n\n\n\n

CS Medica<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Curasight<\/a><\/strong><\/p>\n\n\n\n

Curasight A\/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3<\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

DanCann Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Evaxion Biotech<\/a><\/strong><\/p>\n\n\n\n

Strong validation of Evaxion\u2019s AI-Immunology\u2122 platform in multiple clinical trials (Link<\/a>)<\/p>\n\n\n\n

ExpreS2ion<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Fluoguide<\/a><\/strong><\/p>\n\n\n\n

FluoGuide A\/S submits Clinical Trial Application for phase II trial in head and neck cancer<\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Genmab<\/a><\/strong><\/p>\n\n\n\n

DNB Markets lowered their price target from DKK 2,600 to DKK 2,500, Redburn to DKK 2,899, Barclays to DKK 2,100 from DKK 2,500, and Cowen to DKK 2,000 from DKK 2,015<\/p>\n\n\n\n

Gubra<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Initiator Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/p>\n\n\n\n

IO Biotech<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Pila Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Saniona<\/a><\/strong><\/p>\n\n\n\n

Saniona Initiates SAN711 Biomarker Study (Link<\/a>)<\/p>\n\n\n\n

Saniona Ion Channel Research Collaboration with Boehringer Ingelheim Reaches Milestone (Link<\/a>)<\/p>\n\n\n\n

Scandion Oncology<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

SynAct Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

ViroGates<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

Zealand Pharma<\/a><\/strong><\/p>\n\n\n\n

Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide (Link<\/a>)<\/p>\n\n\n\n

Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism (Link<\/a>)<\/p>\n\n\n\n

Y-mAbs Therapeutic<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

2cureX<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Share price development – Danish stocks<\/strong><\/p>\n\n\n\n

On average, the Danish biotech and healthcare stocks delivered a negative return of 3.8%. Most notably, Zealand Pharma<\/a><\/strong> announced an FDA breakthrough therapy designation, and two phase III trials in Mash for Survodutide were initiated. However, the company also announced a delay in the approval of Dasiglyucagon in the U.S. The company got international awareness as well in CNBC (Link<\/a>). Furthermore, Saniona<\/a><\/strong> initiated a biomarker study with SAN711 and received MEUR 0.5 after they reached a milestone as the partnership with Boehringer Ingelheim reached a milestone. Acarix <\/a><\/strong>got new orders, Biosergen<\/a><\/strong> completed enrollment of the first cohort in trial with BSG005, Evaxion<\/a><\/strong> saw additional validation of their AI platform, Fluoguide<\/a><\/strong> submitted an application for a phase II trial in head and neck cancer. Finally, Genmab<\/a><\/strong> got several new price targets.<\/p>\n\n\n\n

Gubra<\/a><\/strong> continues to be the best-performing stock year-to-date with a return of 286%. Pila Pharma<\/a><\/strong>, Zealand Pharma<\/a><\/strong>, Cessatech<\/a>,<\/strong> and Y-mAbs Therapeutic<\/a><\/strong> have also generated returns of over 100% in 2024.<\/p>\n\n\n\n

Investment case for Curasight<\/a><\/strong><\/p>\n\n\n\n

Overview of share price development the past week, year-to-date, and the last twelve month<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Nordic Biotech & Healthcare Developments<\/mark><\/strong><\/p>\n\n\n\n

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC)<\/strong> fell 1.1% to 66,10. The index has had a strong performance since the beginning of October last year and it has now not only surpassed the KPNGX index but it has also joined the larger indices regarding performance. In the past 12 months, the KPHC index has thus had higher volatility but is now among the same performance as C25 and S30 – far better than the other Nordic growth exchange stocks.<\/p>\n\n\n\n

Chart development for KPHC vs. C25, S30, and KPNGX indices the past year<\/strong><\/p>\n\n\n\n

\"\"
The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.<\/sup><\/figcaption><\/figure>\n\n\n\n

Diagonal Bio became the winner for the second week in a row!<\/strong><\/p>\n\n\n\n

Diagonal Bio AB<\/a> (99%)<\/strong> is developing a platform under the name Panviral to detect and diagnose small sections of pathogen genomes, such as viruses, bacteria, and fungi. In addition to the main business, service, and associated ancillary services are also offered. The company announced successful external validation of LAMPlify\u00ae for viruses in pigs and another pilot study is to come for LAMPify in horses.<\/p>\n\n\n\n

Dignitana AB<\/a> (46%)<\/strong> main focus is to develop, manufacture, and distribute medical aids that are primarily used as a scalp cooling system in chemotherapy treatment, where the purpose is to eliminate or greatly reduce hair loss. The stock rose 37% between 1 am and 2 am on October 9 without any news.<\/p>\n\n\n\n

Spermosens AB<\/a> (23%)<\/strong> specializes in the development of medical devices. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical data and potential fertilization.<\/p>\n\n\n\n

Resources: Refinitiv Eikon, Cision, Nordnet & company websites<\/strong><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks declined 1.1%. Most notably, Zealand Pharma initiated two new phase 3 studies in MASH with Survodutide, while FDA approval for Dasiglucagon was delayed. Further, Acarix got a new order, Genmab […]<\/p>\n","protected":false},"author":11,"featured_media":43132,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[9,29,165,205,163],"tags":[],"class_list":["post-44278","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-en-investeringscases","category-investeringscases","category-investment-cases","category-news","category-sector-cases"],"acf":[],"yoast_head":"\nZealand Pharma with major updates and Saniona received milestone payment | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zealand Pharma with major updates and Saniona received milestone payment | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks declined 1.1%. Most notably, Zealand Pharma initiated two new phase 3 studies in MASH with Survodutide, while FDA approval for Dasiglucagon was delayed. Further, Acarix got a new order, Genmab […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-15T10:06:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-24T10:06:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"724\" \/>\n\t<meta property=\"og:image:height\" content=\"418\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Zealand Pharma with major updates and Saniona received milestone payment\",\"datePublished\":\"2024-10-15T10:06:00+00:00\",\"dateModified\":\"2024-10-24T10:06:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/\"},\"wordCount\":883,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"articleSection\":[\"All investment Cases\",\"Investeringscases\",\"Investment cases\",\"News\",\"Sector cases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/\",\"name\":\"Zealand Pharma with major updates and Saniona received milestone payment | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"datePublished\":\"2024-10-15T10:06:00+00:00\",\"dateModified\":\"2024-10-24T10:06:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"width\":724,\"height\":418},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"All investment Cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Zealand Pharma with major updates and Saniona received milestone payment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zealand Pharma with major updates and Saniona received milestone payment | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/","og_locale":"en_US","og_type":"article","og_title":"Zealand Pharma with major updates and Saniona received milestone payment | Kapital Partner A\/S","og_description":"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks declined 1.1%. Most notably, Zealand Pharma initiated two new phase 3 studies in MASH with Survodutide, while FDA approval for Dasiglucagon was delayed. Further, Acarix got a new order, Genmab […]","og_url":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2024-10-15T10:06:00+00:00","article_modified_time":"2024-10-24T10:06:36+00:00","og_image":[{"width":724,"height":418,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","type":"image\/jpeg"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Zealand Pharma with major updates and Saniona received milestone payment","datePublished":"2024-10-15T10:06:00+00:00","dateModified":"2024-10-24T10:06:36+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/"},"wordCount":883,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","articleSection":["All investment Cases","Investeringscases","Investment cases","News","Sector cases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/","url":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/","name":"Zealand Pharma with major updates and Saniona received milestone payment | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","datePublished":"2024-10-15T10:06:00+00:00","dateModified":"2024-10-24T10:06:36+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","width":724,"height":418},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/zealand-pharma-with-major-updates-and-saniona-received-milestone-payment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"All investment Cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/"},{"@type":"ListItem","position":3,"name":"Zealand Pharma with major updates and Saniona received milestone payment"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/44278"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=44278"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/44278\/revisions"}],"predecessor-version":[{"id":44279,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/44278\/revisions\/44279"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/43132"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=44278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=44278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=44278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}